Laboratory response to intranasal desmopressin in women with menorrhagia and platelet dysfunction

Haemophilia

Volumn 14, Issue 3, 2008, Pages 571-578

  Rose, Shelonitda S ^a   Faiz, A ^a   Miller, C H ^b   Saidi, P ^a   Philipp, C S ^a  

^a ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^b NATIONAL CENTER ON BIRTH DEFECTS AND DEVELOPMENTAL DISABILITIES   (United States)

Author keywords

Intranasal desmopressin; Menorrhagia; Platelet dysfunction

Indexed keywords

ADENOSINE TRIPHOSPHATE; BLOOD CLOTTING FACTOR 8C; COLLAGEN; DESMOPRESSIN; RISTOCETIN; VON WILLEBRAND FACTOR;

ADULT; ANALYZER; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFICACY; FEMALE; HUMAN; IN VITRO STUDY; MENORRHAGIA; MENSTRUAL CYCLE; MENSTRUATION; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION; THROMBOCYTE DYSFUNCTION; THROMBOCYTE FUNCTION;

ADENOSINE TRIPHOSPHATE; ADMINISTRATION, INTRANASAL; ADOLESCENT; ADULT; BLEEDING TIME; BLOOD PLATELET DISORDERS; DEAMINO ARGININE VASOPRESSIN; FACTOR VIII; FEMALE; HEMOSTATICS; HUMANS; MENORRHAGIA; MIDDLE AGED; PLATELET AGGREGATION; SEVERITY OF ILLNESS INDEX; VON WILLEBRAND FACTOR;

EID: 43149092700     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2008.01655.x     Document Type: Article

References (43)

1. Ochler MK, Rees MC. Menorrhagia: An update. Acta Obstet Gynecol Scand 2003; 82: 405-22.
2. Rees MC. Role of menstrual blood loss measurements in management of complaints of excessive menstrual bleeding. Br J Obstet Gynaecol 1991; 98: 327-8.
3. Kadir RA, Economides DL, Sabin CA, Owens D, Lee CA. Frequency of inherited bleeding disorders in women with menorrhagia. Lancet 1998; 351: 485-9.
4. Edlund M, Blomback M, von Schoultz B, Anderson O. On the value of menorrhagia as a predictor for coagulation disorders. Am J Hematol 1996; 53: 234-8.
5. Dilley A, Drews C, Miller C et al. von Willebrand disease and other inherited bleeding disorders in women with diagnosed menorrhagia. Obst Gynaecol 2001; 97: 630-6.
6. Philipp CS, Dilley A, Miller CH et al. Platelet functional defects in women with unexplained menorrhagia. J Thromb Haemost 2003; 1: 477-84.
7. Miller CH, Heit JA, Kouides PA et al. Laboratory characteristics of women with menorrhagia: A multi-site U.S. study. J Thromb Haemost 2007; 5 (Suppl. 2): P-M-187.
8. Manucci PM, Pareti FI, Ruggeri ZM, Capitanio A. 1-Deamino-8-D-arginine vasopressin: A new pharmacological approach to the management of hemophilia and von Willebrand's disease. Lancet 1977; 1: 869-72.
9. Manucci PM, Canciani MT, Rota L, Donovan BS. Response of factor VIII/von Willebrand factor to DDAVP in healthy subjects and patients with hemophilia A and von Willebrand's disease. Br J Haematol 1981; 47: 283-93.
10. Warrier AI, Lusher JM. DDAVP: A useful alternative to blood components in moderate hemophilia A and von Willebrand disease. J Pediatr 1983; 102: 228-33.
11. de la Fuente B, Kasper CK, Rickles FR, Hoyer LW. Response of patients with mild and moderate hemophilia A and von Willebrand's disease to treatment with desmopressin. Ann Intern Med 1985; 103: 6-14.
12. Lethagen S, Harris AS, Nilsson IM. Intranasal desmopressin (DDAVP) by spray in mild hemophilia A and von Willebrand's disease type I. Blut 1990; 60: 187-91.
13. Rose EH, Aledort LM. Nasal spray desmopressin (DDAVP) for mild hemophilia A and von Willebrand disease. Ann Intern Med 1991; 114: 563-8.
14. Seremitis SV, Aledort LM. Desmopressin nasal spray for hemophilia A and type I von Willebrand disease (Letter). Ann Intern Med 1997; 126: 744-5.
15. De Sio L, Mariani G, Muzzucconi MG, Chistolini A, Tirindelli MC, Mandelli F. Comparison between subcutaneous and intravenous DDAVP in mild and moderate hemophilia A. Thromb Haemost 1985; 54: 387-9.
16. Mannucci PM, Vicente V, Alberca I et al. Intravenous and subcutaneous administration of desmopressin (DDAVP) to hemophiliacs: Pharmacokinetics and factor VIII responses. Thromb Haemost 1987; 58: 1037-9.
17. Sakariassen KS, Cattaneo M, van den Berg A, Ruggeri ZM, Manucci PM, Sixma JJ. DDAVP enhances platelet adherence and platelet aggregate growth on human artery endothelium. Blood 1984; 64: 229-36.
18. Cash JD, Gader AM, da Costa J. The release of plasminogen activator and factor VIII to lysine vasopressin, arginine vasopressin, 1-desamino-8-D-arginine vasopressin, angiotensin and oxytocin in man. Br J Haematol 1974; 27: 363-4.
19. Manucci PM, Aberg M, Nilsson IM, Robertson B. Mechanism of plasminogen activator and factor VIII increase after vasoactive drugs. Br J Haematol 1975; 30: 81-93.
20. Kobrinsky NL, Israels ED, Gerrard JM et al. Shortening of bleeding time by 1-deamino-8-D-arginine vasopressin in various bleeding disorders. Lancet 1984; 1: 1145-8.
21. Schulman S, Johnsson H, Egberg N, Blomback M. DDAVP-induced correction of prolonged bleeding time in patients with congenital platelet function defects. Thromb Res 1987; 45: 165-74.
22. Kentro TB, Lottenberg R, Kitchens CS. Clinical efficacy of desmopressin acetate for hemostatic control in patients with primary platelet disorders undergoing surgery. Am J Haematol 1987; 24: 215-9.
23. DiMichele DM, Hathaway WE. Use of DDAVP in inherited and acquired platelet dysfunction. Am J Hematol 1990; 33: 39-45.
24. Rao AK, Ghosh S, Sun L et al. Mechanisms of platelet dysfunction and response to DDAVP in patients with congenital platelet function defects. Thromb Haemost 1995; 74: 1071-8.
25. Manucci PM, Remuzzi G, Pusineri F et al. Deamino-8-D-arginine vasopressin shortens the bleeding time in uremia. N Engl J Med 1983; 308: 8-12.
26. Manucci PM, Vicente V, Vianello L et al. Controlled trial of desmopressin in liver cirrhosis and other conditions associated with prolonged bleeding time. Blood 1986; 67: 1148-53.
27. Lethagen S, Rugarn P. The effect of DDAVP and placebo on platelet function and prolonged bleeding time induced by oral acetyl salicylic acid intake in healthy volunteers. Thromb Haemost 1992; 67: 185-6.
28. Schulman S, Johnsson H. Heparin, DDAVP and the bleeding time. Thromb Haemost 1991; 65: 242-4.
29. Stubner SS, Zielske D, Rossaint R. Comparison between nasal and intravenous desmopressin for the treatment of aminosalicylic acid-induced platelet dysfunction. Eur J Anaesthesiol 2002; 19: 647-51.
30. Rydzewski A, Rowinski M, Mysliwiec M. Shortening of bleeding time after intranasal administration of 1-deamino-8-D-arginine vasopressin to patients with chronic uremia. Folia Haematol Int Mag Klin Morphol Blutforsch 1986; 113: 823-30.
31. Kouides PA, Heit JA, Philipp CS et al. The effect of intranasal desmopressin vs oral tranexamic acid on menstrual blood loss among women with menorrhagia and abnormal laboratory hemostasis: A multicenter, randomized cross-over study. J Thromb Haemost 2007; 5 (Suppl. 2): P-M-183.
32. Byams VR, Dowling NF, Heit JA et al. Quality of life (QOL) evaluation in women with menorrhagia and abnormal hemostasis testing participating in a cross-over study of intranasal desmopressin and oral tranexamic acid. J Thromb Haemost 2007; 5(Suppl. 2): P-S-189.
33. Machin SJ, Preston E. Guidelines on platelet function testing. J Clin Pathol 1988; 41: 1322-30.
34. Miller CH, Platt SJ, Daniele C, Kaczor D. Evaluation of two automated methods for measurement of the ristocetin cofactor activity of von Willebrand factor. Thromb Haemost 2002; 88: 56-9.
35. Higham JM, O'Brien PMS, Shaw RW. Assessment of menstrual blood loss using a pictorial chart. Br J Obstet Gynaecol 1990; 97: 734-9.
36. Janssen CAH, Scholten PC, Heintz APM. A simple visual assessment technique to discriminate between menorrhagia and normal menstrual blood loss. Obstet Gynecol 1995; 85: 977-82.
37. Leissinger C, Becton D, Cornell C, Gill JC. High-dose DDAVP intranasal spray (Stimate ®) for the prevention and treatment of bleeding in patients with mild hemophilia A, mild or moderate type I von Willebrand disease and symptomatic carriers of hemophilia A. Haemophilia 2001; 7: 258-66.
38. Lethagen S, Tenvall GR. Self-treatment with desmopressin intranasal spray in patients with bleeding disorders: Effect on bleeding symptoms and socioeconomic factors. Ann Hematol 1993; 66: 257-60.
39. Kundu SK, Heilmann EJ, Sio R, Garcia C, Davidson RM, Ostgaard RA. Description of an in vitro platelet function analyzer-PFA-100. Semin Thromb Hemost 1995; 21: 106-12.
40. Philipp CS, Miller CH, Faiz A et al. Screening women with menorrhagia for underlying bleeding disorders: The utility of the platelet function analyzer and bleeding time. Haemophilia 2005; 11: 497-503.
41. Cattaneo M, Lecchi A, Agati B, Lombardi R, Zighetti ML. Evaluation of platelet function with the PFA-100 system in patients with congenital defects of platelet secretion. Thromb Res 1999; 96: 213-7.
42. Balduini CL, Noris P, Belletti S, Spedini P, Gamba G. In vitro and in vivo effects of desmopressin on platelet function. Haematologica 1999; 84: 891-6.
43. Kadir RA, Lee CA, Sabin CA, Pollard D, Economides DL. DDAVP nasal spray for treatment of menorrhagia in women with inherited bleeding disorders: a randomized placebo-controlled crossover study. Haemophilia 2002; 8: 787-93.